Newborn Screening for Lysosomal Storage Diseases
Open Access
- 1 February 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 61 (2), 335-346
- https://doi.org/10.1373/clinchem.2014.225771
Abstract
BACKGROUND: There is worldwide interest in newborn screening for lysosomal storage diseases because of the development of treatment options that give better results when carried out early in life. Screens with high differentiation between affected and nonaffected individuals are critical because of the large number of potential false positives. CONTENT: This review summarizes 3 screening methods: (a) direct assay of enzymatic activities using tandem mass spectrometry or fluorometry, (b) immunocapture-based measurement of lysosomal enzyme abundance, and (c) measurement of biomarkers. Assay performance is compared on the basis of small-scale studies as well as on large-scale pilot studies of mass spectrometric and fluorometric screens. SUMMARY: Tandem mass spectrometry and fluorometry techniques for direct assay of lysosomal enzymatic activity in dried blood spots have emerged as the most studied approaches. Comparative mass spectrometry vs fluorometry studies show that the former better differentiates between nonaffected vs affected individuals. This in turn leads to a manageable number of screen positives that can be further evaluated with second-tier methods.Keywords
Funding Information
- University of Washington
- National Institutes of Health (DK67859)
- Genzyme
- BioMarin Corp.
- PerkinElmer
- Shire
This publication has 80 references indexed in Scilit:
- Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease PatientsPLOS ONE, 2013
- Newborn Screening for Lysosomal Storage Disorders in HungaryPublished by Springer Science and Business Media LLC ,2012
- New Substrates and Enzyme Assays for the Detection of Mucopolysaccharidosis III (Sanfilippo Syndrome) Types A, B, C, and D by Tandem Mass SpectrometryBioconjugate Chemistry, 2012
- Disease-specific non–reducing end carbohydrate biomarkers for mucopolysaccharidosesNature Chemical Biology, 2012
- Comparative Triplex Tandem Mass Spectrometry Assays of Lysosomal Enzyme Activities in Dried Blood Spots Using Fast Liquid Chromatography: Application to Newborn Screening of Pompe, Fabry, and Hurler DiseasesAnalytical Chemistry, 2011
- Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots:Application to Screening Newborns for Mucopolysaccharidosis IVAClinical Chemistry, 2011
- Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis II (Hunter Syndrome)Analytical Chemistry, 2010
- Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome)Analytical Chemistry, 2010
- Multiplex Lysosomal Enzyme Activity Assay on Dried Blood Spots Using Tandem Mass SpectrometryPublished by Springer Science and Business Media LLC ,2009
- Newborn Screening for Krabbe Disease: the New York State ModelPediatric Neurology, 2009